QC laboratory Controls & Management-ppt.pdf
- 2. Laboratory controls General Controls Sampling Testing of RM, PM, Excipients, APIs & FP Validation of Analytical Procedures Certificates of Analysis Stability Monitoring Expiry / shelf life Reserve/Retention Samples Good laboratory practices Documentation 2
- 3. General Controls ▪ The independent quality unit(s) should have at its disposal adequate laboratory facilities. ▪ There should be documented procedures describing sampling, testing, approval or rejection of materials, and recording and storage of laboratory data. ▪ Laboratory records should be maintained in accordance with online testing. ▪ All specifications, sampling plans, and test procedures should be scientifically sound and appropriate to ensure that RMs, PMs, Intermediates, in-process, APIs, FP and labels conform to established standards of quality and/or purity. ▪ Specifications and test procedures should be consistent with those included in the registration / filing. Specifications, sampling plans, and test procedures, including changes to them, should be drafted by the appropriate organizational unit and reviewed and approved by the quality unit(s). 3
- 4. General Controls ▪ Appropriate specifications should be established for RM, PM, Excipients, in-process, APIs & FP in accordance with accepted standards and consistent with the manufacturing process. ▪ The specifications should include a control of the impurities (e.g. organic impurities, inorganic impurities, and residual solvents). If the RM/API/FP has a specification for microbiological purity, appropriate action limits for total microbial counts. ▪ Objectionable organisms should be established and met. If the API/FP has a specification for endotoxins, appropriate action limits should be established and met. 4
- 5. General Controls ▪ Laboratory controls should be followed and documented at the time of performance. Any departures from the above described procedures should be documented, investigated and explained. ▪ Any out-of-specification result obtained should be investigated and documented according to a procedure. This procedure should require analysis of the data, assessment of whether a significant problem exists, allocation of the tasks for corrective actions, and conclusions. Any resampling and/or retesting after OOS results should be performed according to a documented procedure. ▪ Reagents and standard solutions should be prepared and labelled following written procedures. “Use by” dates should be applied as appropriate for analytical reagents or standard solutions. 5
- 6. General Controls ▪ Primary reference standards should be obtained as appropriate for the manufacture of FP/ APIs. The source of each primary reference standard should be documented. Records should be maintained of each primary reference standard’s storage and use in accordance with the supplier’s recommendations. Primary reference standards obtained from an officially recognized source are normally used without testing if stored under conditions consistent with the supplier’s recommendations. ▪ Where a primary reference standard is not available from an officially recognized source, an “in-house primary standard” should be established. Appropriate testing should be performed to establish fully the identity and purity of the primary reference standard. Appropriate documentation of this testing should be maintained. ▪ Secondary reference standards should be appropriately prepared (working standard), identified, tested, approved, and stored. The suitability of each batch of secondary reference standard should be determined prior to first use by comparing against a primary reference standard. Each batch of secondary reference standard should be periodically requalified in accordance with a written protocol. 6
- 7. Sampling The sample taking should be done and recorded in accordance with approved written procedures that describe: • The method of sampling; • The equipment/tools to be used; • The amount of the sample to be taken; • Instructions for any required sub-division of the sample; • The type and condition of the sample container to be used; • The identification of containers sampled; • Any special precautions to be observed, especially with regard to the sampling of sterile or noxious materials; • The storage conditions; 7
- 8. Sampling • Instructions for the cleaning and storage of sampling tools. • Samples should be representative of the batch of materials or homogeneous/ uniform , products from which they are taken. • The sampling plan used should be appropriately justified and based on a risk management approach. • Sample containers should bear a label indicating the contents, with the batch number, the date of sampling and the containers from which samples have been drawn. They should be managed in a manner to minimize the risk of mix-up and to protect the samples from adverse storage conditions 8
- 9. Testing of RM, PM, Excipients, APIs & FP ▪ For each batch of RM, PM, Excipient, intermediate, API & FP, appropriate laboratory tests should be conducted to determine conformance to specifications. ▪ An impurity profile describing the identified and unidentified impurities present in a typical batch produced by a specific controlled production process should normally be established for each API & FP. ▪ The impurity profile should include the identity or some qualitative analytical designation (e.g. retention time), the range of each impurity observed, and classification of each identified impurity (e.g. inorganic, organic, solvent). 9
- 10. Testing of RM, PM, Excipients, APIs & FP ▪ The impurity profile is normally dependent upon the production process and origin of the FP/ API. ▪ Appropriate microbiological tests should be conducted on each batch of intermediate and API where microbial quality is specified. 10
- 11. Testing of RM, PM, Excipients, APIs & FP ▪ Testing methods should be validated. ▪ All testing operations described in the marketing authorization or technical dossier should be carried out according to the approved methods. ▪ The results obtained should be recorded. Results of parameters identified as quality attribute or as critical should be trended and checked to make sure that they are consistent with each other. Any calculations should be critically examined. 11
- 12. Testing of RM, PM, Excipients, APIs & FP ❖ The tests performed should be recorded and the records should include at least the following data: • Name of the material or product and, where applicable, dosage form; • Batch number and, where appropriate, the manufacturer and/or supplier; • References to the relevant specifications and testing procedures; • Test results, including observations and calculations, and reference to any certificates of analysis; • Dates of testing; • Initials of the persons who performed the testing; • Initials of the persons who verified the testing and the calculations, where appropriate; • A clear statement of approval or rejection (or other status decision) and the dated signature of the designated responsible person; • Reference to the equipment used. 12
- 13. Testing of RM, PM, Excipients, APIs & FP ▪ All the in-process controls, including those made in the production area by production personnel/IPQC, should be performed according to methods approved by Quality Control and the results recorded. ▪ Special attention should be given to the quality of laboratory reagents, solutions, glassware, reference standards and culture media. They should be prepared and controlled in accordance with written procedures. ▪ Working standards should be established as suitable for their intended use. Their qualification and certification as such should be clearly stated and documented. ▪ Whenever compendial reference standards from an officially recognized source exist, these should preferably be used as primary reference standards unless fully justified. 13
- 14. Microbial testing of RM, PM, Excipients, APIs & FP ▪ Laboratory reagents, solutions, reference standards and culture media should be marked with the preparation and opening date and the signature of the person who prepared them with proper valid date. ▪ The expiry date of reagents and culture media should be indicated on the label, together with specific storage conditions. In addition, for volumetric solutions, the last date of standardization and the last current factor should be indicated. ▪ Culture media should be prepared in accordance with the media manufacturer’s requirements unless scientifically justified. ▪ The performance of all culture media should be verified prior to use. Used microbiological media and strains should be decontaminated according to a standard procedure and disposed of in a manner to prevent the cross- contamination and retention of residues. ▪ The in-use shelf life of microbiological media should be established, documented and scientifically justified. 14
- 15. Validation of Analytical Procedures ▪ Analytical methods should be validated unless the method employed is included in the relevant pharmacopoeia or other recognized standard reference. ▪ The suitability of all testing methods used should be verified under actual conditions of use and documented. ▪ Methods should be validated to include consideration of characteristics included within the ICH guidelines on validation of analytical methods. The degree of analytical validation performed should reflect the purpose of the analysis and the stage of the API/FP production process. ▪ Appropriate qualification of analytical equipment should be considered before starting validation of analytical methods. ▪ Complete records should be maintained of any modification of a validated analytical method. Such records should include the reason for the modification and appropriate data to verify that the modification produces results that are as accurate and reliable as the established method. 15
- 16. COA ▪ Authentic Certificates of Analysis should be issued for each batch of FP on request. ▪ Information on the name of the FP including where appropriate its grade, the batch number, and the date of release should be provided on the Certificate of Analysis. ▪ The expiry date should be provided on the label and Certificate of Analysis. ▪ The Certificate should list each test performed in accordance with compendial or customer requirements, including the acceptance limits, and the numerical results obtained (if test results are numerical). ▪ Certificates should be dated and signed by authorized personnel of the quality unit(s) and should show the name, address and telephone number of the original manufacturer. 16
- 17. Stability Monitoring of APIs ▪ A documented, on-going testing program should be designed to monitor the stability characteristics of FP, and the results should be used to confirm appropriate storage conditions and expiry dates. ▪ The test procedures used in stability testing should be validated and be stability indicating. ▪ Stability samples should be stored in containers that simulate the market container. ▪ Stability samples can be packaged in bags of the same material and in smaller-scale drums of similar or identical material composition to the market packing mode. 17
- 18. Stability Monitoring ▪ Normally the first three commercial production batches should be placed on the stability monitoring program to confirm the expiry / shelf life date. ▪ Thereafter, at least one batch per year of FP manufactured (unless none is produced that year) should be added to the stability monitoring program and tested at least annually to confirm the stability (annual addition batch for stability). ▪ For FP with short shelf-lives, testing should be done more frequently. For example, for those biotechnological/biologic and other APIs with shelf-lives of one year or less, stability samples should be obtained and should be tested monthly for the first three months, and at three month intervals. ▪ Where appropriate, the stability storage conditions should be consistent with the ICH guidelines on stability. 18
- 19. Expiry / shelf life ▪ FP expiry or shelf life should be based on an evaluation of data derived from stability studies. Common practice is to use a expiry date. ▪ FP expiry date can be based on pilot scale batches if (1) the pilot batches employ a method of manufacture and procedure that simulates the final process to be used on a commercial manufacturing scale; and (2) the quality of the FP represents the material to be made on a commercial scale. ▪ A representative sample should be taken for the purpose of performing a expiry. 19
- 20. Reserve/ Retention Samples ▪ The packaging and holding of reserve samples is for the purpose of potential future evaluation of the quality of batches of FP and not for future stability testing purposes. ▪ Appropriately identified reserve samples of each FP batch should be retained for one year after the expiry date. ▪ The reserve sample should be stored in the same packaging system in which the FP is stored or in one that is equivalent to or more protective than the marketed packaging system. ▪ Sufficient quantities should be retained to conduct at least two full compendial analyses or, when there is no pharmacopoeial monograph, two full specification analyses. 20
- 21. Reserve/ Retention Samples ▪ A sample of a fully packaged unit from a batch of finished product. It is stored for identification purposes. ▪ For example, presentation, packaging, labelling, patient information leaflet, batch number, expiry date should the need arise during the shelf life of the batch concerned. ▪ For finished products, in many instances the reference and retention samples will be presented identically, i.e. as fully packaged units. In such circumstances, reference and retention samples may be regarded as interchangeable. 21
- 22. Reserve/ Retention Samples • It is necessary for the manufacturer, importer or site of batch release, as specified retention samples from each batch of finished product. • Availability of printed materials as part of the reference and/or retention sample of the finished product can be accepted. • The retention samples serve as a record of the batch of finished product and can be assessed in the event of, for example, a dosage form quality complaint, a query relating to compliance with the marketing authorization, a labelling/packaging query or a pharmacovigilance report. • Records of traceability of samples should be maintained and be available for review by competent authorities. 22
- 23. Good Laboratory Practices ▪ Laboratory instrument should not be routinely moved between high risk areas to avoid accidental cross-contamination. ▪ The use of outside laboratories, in conformity with the principles of GLP. Contract Analysis, can be accepted for particular reasons, but this should be stated in the Quality Control records. ▪ Proper labelling for samples, instruments, standards and chemicals etc. ▪ On date calibrations shall be performed. ▪ Cleaning glass ware should be followed according to SOP. ▪ On time recording shall be performed during analysis. ▪ Hand writings should be legible and clear. ▪ On time Log books should be updated. ▪ If discrepancy happened deviation/ incident/OOS/OOT shall be raised. ▪ Proper sequence as per SOP and testing method ▪ Verification of vials / glassware condition. 23
- 24. Documentation An important part of this documentation deals with Quality Control and the following details should be readily available to the Quality Control Department: ▪ Specifications; ▪ Procedures describing sampling, testing, records (including test worksheets and/or laboratory notebooks), recording and verifying; ▪ Procedures for and records of the calibration/qualification of instruments and maintenance of equipment; ▪ A procedure for the investigation of Out of Specification and Out Of Trend results; ▪ Testing reports and/or certificates of analysis; ▪ Data from environmental (air, water and other utilities) monitoring, where required; ▪ Validation records of test methods, where applicable. ▪ If any change related spec/ method/document etc. change control to be raised. 24
- 25. Documentation ▪ Some kinds of data (e.g. tests results, yields, environmental controls) should be recorded in a manner permitting trend evaluation. ▪ Any out of trend or out of specification data should be addressed and subject to investigation. ▪ In addition to the information which is part of the batch documentation, other raw data such as laboratory notebooks, calibration data and/or records should be retained and readily available. 25